A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of the Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Male Subjects
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Zanubrutinib (Primary) ; Rifabutin
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; COVID 2019 infections; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors BeiGene
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.
- 17 Mar 2021 Planned End Date changed from 1 Feb 2021 to 1 Nov 2021.
- 04 Nov 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Nov 2020.